

David Llobet-Navas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7871888/publications.pdf>

Version: 2024-02-01

43
papers

5,209
citations

172207

29
h-index

276539

41
g-index

47
all docs

47
docs citations

47
times ranked

9210
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50,742 1,430	4.3	1,430
2	NF- κ B in development and progression of human cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 475-482.	1.4	926
3	An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma. Cell, 2011, 147, 370-381.	13.5	671
4	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nature Medicine, 2014, 20, 1130-1137.	15.2	349
5	PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations. Human Pathology, 2006, 37, 1465-1472.	1.1	134
6	Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Modern Pathology, 2005, 18, 719-727.	2.9	110
7	Abnormalities in the NF- κ B family and related proteins in endometrial carcinoma. Journal of Pathology, 2004, 204, 569-577.	2.1	101
8	Autophagy in the physiological endometrium and cancer. Autophagy, 2021, 17, 1077-1095.	4.3	100
9	Proteasome Inhibitors Induce Death but Activate NF- κ B on Endometrial Carcinoma Cell Lines and Primary Culture Explants. Journal of Biological Chemistry, 2006, 281, 22118-22130.	1.6	94
10	Inhibition of the autocrine IL-6/JAK2-STAT3/calprotectin axis as targeted therapy for HR+/HER2+ breast cancers. Genes and Development, 2015, 29, 1631-1648.	2.7	94
11	Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Research, 2015, 25, 257-267.	2.4	94
12	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes and Development, 2017, 31, 553-566.	2.7	87
13	Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers. Cell, 2014, 159, 1461-1475.	13.5	77
14	Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Human Pathology, 2012, 43, 632-643.	1.1	75
15	The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes and Development, 2014, 28, 765-782.	2.7	66
16	Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy, 2017, 13, 608-624.	4.3	65
17	Survivin Expression in Endometrial Carcinoma. International Journal of Gynecological Pathology, 2005, 24, 247-253.	0.9	62
18	FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Laboratory Investigation, 2005, 85, 885-894.	1.7	59

#	ARTICLE	IF	CITATIONS
19	Endometrial Carcinoma: Specific Targeted Pathways. <i>Advances in Experimental Medicine and Biology</i> , 2017, 943, 149-207.	0.8	53
20	Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. <i>Anti-Cancer Drugs</i> , 2008, 19, 115-124.	0.7	51
21	CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. <i>Oncogene</i> , 2008, 27, 2513-2524.	2.6	48
22	Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. <i>Blood</i> , 2009, 113, 4595-4603.	0.6	48
23	A Novel Three-Dimensional Culture System of Polarized Epithelial Cells to Study Endometrial Carcinogenesis. <i>American Journal of Pathology</i> , 2010, 176, 2722-2731.	1.9	46
24	CK2 β Is Expressed in Endometrial Carcinoma and Has a Role in Apoptosis Resistance and Cell Proliferation. <i>American Journal of Pathology</i> , 2009, 174, 287-296.	1.9	42
25	HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. <i>Breast Cancer Research</i> , 2015, 17, 149.	2.2	42
26	Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. <i>British Journal of Dermatology</i> , 2008, 158, 496-504.	1.4	41
27	The MicroRNA 424/503 Cluster Reduces CDC25A Expression during Cell Cycle Arrest Imposed by Transforming Growth Factor β 2 in Mammary Epithelial Cells. <i>Molecular and Cellular Biology</i> , 2014, 34, 4216-4231.	1.1	39
28	The number of titrated microRNA species dictates ceRNA regulation. <i>Nucleic Acids Research</i> , 2018, 46, 4354-4369.	6.5	32
29	KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels. <i>American Journal of Pathology</i> , 2011, 178, 1529-1543.	1.9	30
30	Nuclear factor- κ B activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. <i>Human Pathology</i> , 2008, 39, 994-1001.	1.1	25
31	A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF- β 2 in mouse endometrium. <i>Cell Death and Differentiation</i> , 2017, 24, 1443-1458.	5.0	24
32	Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma. <i>Cell Death and Disease</i> , 2016, 7, e2358-e2358.	2.7	20
33	TNFR-Associated Factor 2 Deficiency in B Lymphocytes Predisposes to Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Mice. <i>Journal of Immunology</i> , 2012, 189, 1053-1061.	0.4	18
34	ER α -mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a critical role for TNF α and IL1 α in lumen formation and maintenance. <i>Journal of Cell Science</i> , 2012, 125, 1929-44.	1.2	11
35	ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. <i>Molecular Oncology</i> , 2022, 16, 2235-2259.	2.1	9
36	A microRNA Cluster Controls Fat Cell Differentiation and Adipose Tissue Expansion By Regulating SNGC. <i>Advanced Science</i> , 2022, 9, 2104759.	5.6	9

#	ARTICLE	IF	CITATIONS
37	Targeted therapies in gynecologic cancers and melanoma. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 262-273.	1.0	8
38	The oral KIF11 inhibitor 4SCâ€205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. <i>Clinical and Translational Medicine</i> , 2021, 11, e533.	1.7	7
39	Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer. <i>Cancers</i> , 2022, 14, 2842.	1.7	6
40	miRâ€424/503 modulates Wnt/Î²â€catenin signaling in the mammary epithelium by targeting LRP6. <i>EMBO Reports</i> , 2021, 22, e53201.	2.0	2
41	A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis. <i>JCI Insight</i> , 2022, 7, .	2.3	2
42	Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro. <i>Cancers</i> , 2021, 13, 4845.	1.7	0
43	ÂÂÂÂÂN-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL. <i>Blood</i> , 2014, 124, 487-487.	0.6	0